USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

Tirzepatide also significantly reduced the onset of T2D, with only 1.3% of participants in the treatment groups developing T2D compared to 13.3% in the placebo group (hazard ratio = 0.07, P < 0.001).

Findings at week 176 demonstrated that among patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free, corresponding to a 94% reduction ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Jagatic: Men with diabetes have a 3.5 times greater risk for erectile dysfunction (ED) than men without diabetes. In a 2016 meta-analysis, the prevalence of ED was 37.5% for men with type 1 ...

Findings showed treatment with tirzepatide reduced the risk of time-to-first occurrence of HF outcomes (urgent HF visit, HF hospitalization, oral diuretic intensification, or CV death) by 38% ...

Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor ...

The drug drastically slowed the progression of kidney disease in patients with type 2 diabetes and an increased cardiovascular risk, according to the American Diabetes Association. Tirzepatide ...